SLMT:NASDAQBrera Holdings PLC Analysis
Data as of 2026-07-30 - not real-time
$3.63
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Brera Holdings PLC (SLMT) is trading at $3.63, barely above its calculated support of $3.61 and well below its 20‑day SMA of $4.99 and 50‑day SMA of $5.23, indicating a fragile price footing. The RSI of 34 and a bearish MACD histogram suggest the stock is oversold but still under downward momentum, while a 30‑day volatility of 138% and a beta near 5 signal extreme price swings. Fundamentals are weak: revenue of $4.48 M grew only 5%, operating margin is –71%, and trailing EPS is –$1,689, yet free cash flow appears positive at $49.8 M, creating a stark inconsistency. The DCF‑derived fair value of $161.44 dwarfs the current market cap of $39.96 M, implying a massive valuation gap, but the company’s negative earnings, high max drawdown of –98.8%, and governance turbulence—highlighted by a contested board re‑election and shareholder disputes—raise serious doubts about realizing that upside. Overall, the technical picture is bearish, the financial health is precarious, and the valuation discrepancy is driven more by model assumptions than solid fundamentals.
Given the “Extreme Greed” market sentiment (Fear & Greed Index 84.5) and a decreasing volume trend, speculative interest may be inflating short‑term price action, but the combination of high volatility, liquidity constraints, and unresolved corporate governance issues makes the stock a high‑risk proposition. Investors should weigh the potential upside against the likelihood of continued price deterioration and consider the lack of any dividend or sustainable earnings stream before committing capital.
Given the “Extreme Greed” market sentiment (Fear & Greed Index 84.5) and a decreasing volume trend, speculative interest may be inflating short‑term price action, but the combination of high volatility, liquidity constraints, and unresolved corporate governance issues makes the stock a high‑risk proposition. Investors should weigh the potential upside against the likelihood of continued price deterioration and consider the lack of any dividend or sustainable earnings stream before committing capital.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Price below short‑term moving averages and near support
- Bearish MACD and low RSI indicating continued downside
- Decreasing volume and extreme volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Unclear path to profitability despite positive free cash flow
- Governance concerns from recent board re‑election dispute
- Potential upside if DCF assumptions materialize
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Massive valuation gap between market price and DCF fair value
- Low price‑to‑book ratio of 0.18 suggesting deep discount
- Possible restructuring or strategic pivot that could unlock value
Key Metrics & Analysis
Financial Health
Revenue Growth500.80%
ROE-517.66%
ROA-216.75%
P/B Ratio0.2
Op. Cash Flow$-10700000
Free Cash Flow$49.8M
Industry P/E31.2
Technical Analysis
TrendBearish
RSI34.7
Support$3.61
Resistance$6.63
MA 20$4.99
MA 50$5.23
MA 200$24.42
MACDBearish
VolumeDecreasing
Fear & Greed Index84.54
Valuation
Fair Value$161.44
GradeUndervalued
TypeValue
Risk Assessment
Beta4.80
Volatility138.44%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.